GlassScriptPhysician profile
Tiffany George
NPI 1780004283
$5,958.90
in general payments reported to CMS, 2019-2025
41 companies · $2,051 in 2025
The $2,051 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $91.90 · 2021: $601 · 2022: $760 · 2023: $960 · 2024: $1,495 · 2025: $2,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,439 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,439.00 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,113.54 | 2021-2025 | Erleada, Akeega, Talvey |
| Pfizer INC. | $600.50 | 2022-2025 | |
| Glaxosmithkline, LLC. | $477.16 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $367.62 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $280.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $278.07 | 2023-2025 | Enhertu, Wainua |
| Takeda Pharmaceuticals U.S.A., INC. | $253.09 | 2023-2025 | Iclusig, Alunbrig, Ninlaro |
| Daiichi Sankyo INC. | $251.58 | 2024-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $219.41 | 2022-2025 | Opdivo |
| Taiho Oncology, INC. | $215.18 | 2023-2025 | |
| Incyte Corporation | $176.02 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $133.70 | 2022-2025 | |
| Tersera Therapeutics LLC | $126.19 | 2024-2025 | Zoladex |
| Amgen INC. | $125.00 | 2021 | |
| Astellas Pharma US INC | $123.57 | 2022-2023 | Padcev, Xtandi |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $109.16 | 2025 | |
| Seagen INC. | $91.90 | 2020 | |
| Abbvie INC. | $90.99 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $90.24 | 2024-2025 | |
| Genentech USA, INC. | $80.99 | 2023-2025 | Rozlytrek, Alecensa, Tecentriq |
| Genzyme Corporation | $80.89 | 2024-2025 | |
| Emd Serono, INC. | $78.79 | 2024-2025 | |
| Array Biopharma INC | $65.99 | 2023-2025 | Mektovi, Braftovi, Tukysa |
| Jazz Pharmaceuticals INC. | $55.63 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.91 | 2023-2025 | |
| Lilly USA, LLC | $48.38 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Stemline Therapeutics INC. | $45.58 | 2024 | Elzonris |
| Puma Biotechnology, INC. | $37.88 | 2023-2025 | |
| Beone Medicines USA, INC. | $35.98 | 2025 | Tevimbra, Brukinsa |
| Beigene USA, INC. | $32.03 | 2023-2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $25.65 | 2025 | Qinlock, Tgct |
| Ipsen Biopharmaceuticals, INC | $22.29 | 2024 | Onivyde, Somatuline Depot |
| Celgene Corporation | $21.43 | 2025 | Reblozyl |
| Tempus Ai, INC | $21.22 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2023 | Imbruvica, Epkinly |
| Pharmacosmos Therapeutics INC. | $20.68 | 2025 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $19.71 | 2023 | Sancuso |
| Springworks Therapeutics, INC. | $18.66 | 2024 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $17.65 | 2023 | Empaveli |
| Myriad Genetic Laboratories, INC. | $15.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.